136 related articles for article (PubMed ID: 38545732)
21. New onset of uveitis during anti-tumor necrosis factor treatment for rheumatic diseases.
Wendling D; Paccou J; Berthelot JM; Flipo RM; Guillaume-Czitrom S; Prati C; Dernis E; Direz G; Ferrazzi V; Ristori JM;
Semin Arthritis Rheum; 2011 Dec; 41(3):503-10. PubMed ID: 21862108
[TBL] [Abstract][Full Text] [Related]
22. Demyelinating plaque-associated uveitis.
Hedayatfar A; Anvari P; Herbort CP; Chee SP
Graefes Arch Clin Exp Ophthalmol; 2024 Feb; 262(2):575-582. PubMed ID: 37855958
[TBL] [Abstract][Full Text] [Related]
23. [Retinitis pigmentosa mimicking uveitis. A case report].
Szabó E; Brichová M; Lišková P; Svozílková P; Ríhová E
Cesk Slov Oftalmol; 2013 Mar; 69(1):32-6. PubMed ID: 23822599
[TBL] [Abstract][Full Text] [Related]
24. The Effect of Tumor Necrosis Factor-Alpha Inhibitors on Uveitis in Patients with Ankylosing Spondylitis.
Lee S; Park YJ; Lee JY
J Korean Med Sci; 2019 Nov; 34(42):e278. PubMed ID: 31674159
[TBL] [Abstract][Full Text] [Related]
25. Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey.
Foeldvari I; Nielsen S; Kümmerle-Deschner J; Espada G; Horneff G; Bica B; Olivieri AN; Wierk A; Saurenmann RK
J Rheumatol; 2007 May; 34(5):1146-50. PubMed ID: 17343318
[TBL] [Abstract][Full Text] [Related]
26. The effect of biologic therapy different from infliximab or adalimumab in patients with refractory uveitis due to Behçet's disease: results of a multicentre open-label study.
Santos-Gómez M; Calvo-Río V; Blanco R; Beltrán E; Mesquida M; Adán A; Cordero-Coma M; García-Aparicio ÁM; Valls Pascual E; Martínez-Costa L; Hernández MV; Hernandez Garfella M; González-Vela MC; Pina T; Palmou-Fontana N; Loricera J; Hernández JL; González-Gay MA
Clin Exp Rheumatol; 2016; 34(6 Suppl 102):S34-S40. PubMed ID: 27054359
[TBL] [Abstract][Full Text] [Related]
27. Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patients.
Fabiani C; Vitale A; Rigante D; Emmi G; Bitossi A; Lopalco G; Sota J; Guerriero S; Orlando I; Gentileschi S; Iannone F; Frediani B; Galeazzi M; Vannozzi L; Tosi GM; Cantarini L
Clin Rheumatol; 2019 Feb; 38(2):407-415. PubMed ID: 30099655
[TBL] [Abstract][Full Text] [Related]
28. Intravitreal infliximab for sight-threatening relapsing uveitis in Behçet disease: a pilot study in 15 patients.
Markomichelakis N; Delicha E; Masselos S; Sfikakis PP
Am J Ophthalmol; 2012 Sep; 154(3):534-541.e1. PubMed ID: 22789563
[TBL] [Abstract][Full Text] [Related]
29. [Sarcoid uveitis: Ophthalmologist's and internist's viewpoints].
Sève P; Jacquot R; El Jammal T; Bert A; Jamilloux Y; Kodjikian L; Giorgiutti S
Rev Med Interne; 2023 Mar; 44(3):112-122. PubMed ID: 36642624
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of Th17 differentiation by anti-TNF-alpha therapy in uveitis patients with Behçet's disease.
Sugita S; Kawazoe Y; Imai A; Yamada Y; Horie S; Mochizuki M
Arthritis Res Ther; 2012 May; 14(3):R99. PubMed ID: 22546542
[TBL] [Abstract][Full Text] [Related]
31. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes.
Suhler EB; Smith JR; Wertheim MS; Lauer AK; Kurz DE; Pickard TD; Rosenbaum JT
Arch Ophthalmol; 2005 Jul; 123(7):903-12. PubMed ID: 16009830
[TBL] [Abstract][Full Text] [Related]
32. Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis.
Murphy CC; Ayliffe WH; Booth A; Makanjuola D; Andrews PA; Jayne D
Ophthalmology; 2004 Feb; 111(2):352-6. PubMed ID: 15019389
[TBL] [Abstract][Full Text] [Related]
33. Effectiveness of infliximab, adalimumab and golimumab for non-infectious refractory uveitis in adults.
Borrás-Blasco J; Casterá DE; Cortes X; Abad FJ; Rosique-Robles JD; Mallench LG
Int J Clin Pharmacol Ther; 2015 May; 53(5):377-90. PubMed ID: 25345430
[TBL] [Abstract][Full Text] [Related]
34. TNF inhibition for ophthalmic indications: current status and outlook.
Rifkin LM; Birnbaum AD; Goldstein DA
BioDrugs; 2013 Aug; 27(4):347-57. PubMed ID: 23568177
[TBL] [Abstract][Full Text] [Related]
35. The efficacy of systemic and intravitreal infliximab treatments in an endotoxin-induced uveitis model.
Donmez O; Yaman A; Ozturk T; Aktas S; Altun ZS; Yılmaz O
Cutan Ocul Toxicol; 2019 Dec; 38(4):360-369. PubMed ID: 31213109
[No Abstract] [Full Text] [Related]
36. Infliximab for juvenile idiopathic arthritis-associated uveitis.
Richards JC; Tay-Kearney ML; Murray K; Manners P
Clin Exp Ophthalmol; 2005 Oct; 33(5):461-8. PubMed ID: 16181269
[TBL] [Abstract][Full Text] [Related]
37. Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis.
Saurenmann RK; Levin AV; Rose JB; Parker S; Rabinovitch T; Tyrrell PN; Feldman BM; Laxer RM; Schneider R; Silverman ED
Rheumatology (Oxford); 2006 Aug; 45(8):982-9. PubMed ID: 16461435
[TBL] [Abstract][Full Text] [Related]
38. Anti-Tumor Necrosis Factor α versus Tocilizumab in the Treatment of Refractory Uveitic Macular Edema: A Multicenter Study from the French Uveitis Network.
Leclercq M; Andrillon A; Maalouf G; Sève P; Bielefeld P; Gueudry J; Sené T; Moulinet T; Rouvière B; Sène D; Desbois AC; Domont F; Touhami S; El Chamieh C; Cacoub P; Bodaghi B; Biard L; Saadoun D
Ophthalmology; 2022 May; 129(5):520-529. PubMed ID: 34793830
[TBL] [Abstract][Full Text] [Related]
39. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation.
Galor A; Perez VL; Hammel JP; Lowder CY
Ophthalmology; 2006 Dec; 113(12):2317-23. PubMed ID: 16996615
[TBL] [Abstract][Full Text] [Related]
40. Reactivation of juvenile idiopathic arthritis associated uveitis with posterior segment manifestations following anti-SARS-CoV-2 vaccination.
Mahendradas P; Mishra SB; Mangla R; Sanjay S; Kawali A; Shetty R; Dharmanand B
J Ophthalmic Inflamm Infect; 2022 Apr; 12(1):15. PubMed ID: 35476156
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
